Study guide

10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

Key Takeaways Explain This Topic AI

Rh(D)-negative patients without anti-D antibodies receive 300 mcg of Rho(D) immune globulin at about 28 weeks and within 72 hours after delivery of an Rh(D)-positive infant.

One 300-mcg vial covers about 30 mL of fetal whole blood (15 mL of fetal red cells); a Kleihauer-Betke test or flow cytometry after delivery or trauma determines whether more vials are needed.

Anti-D immune globulin is also given for bleeding, trauma, ectopic or molar pregnancy, amniocentesis, CVS, and external cephalic version, while ACOG (2024) suggests forgoing it for abortion or loss before 12 weeks.

In a sensitized pregnancy, a critical anti-D titer (commonly 1:16) triggers middle cerebral artery peak systolic velocity Doppler; a value above 1.5 MoM suggests moderate-to-severe fetal anemia.

Anti-Kell antibodies can cause severe fetal anemia at low titers because they suppress fetal red-cell production, so a lower critical titer (1:8) and Doppler surveillance are used.

Last updated: October 2026

Pathophysiology

When an Rh(D)-negative person is exposed to Rh(D)-positive fetal red cells, through fetomaternal hemorrhage at delivery, bleeding, trauma, or procedures, they can form anti-D antibodies . The first affected pregnancy is usually spared because the primary response is slow and mostly IgM. In later Rh(D)-positive pregnancies, IgG anti-D crosses the placenta and coats fetal red cells, causing hemolysis , fetal anemia, extramedullary hematopoiesis, and in severe cases hydrops fetalis (high-output heart failure, ascites, edema) and fetal death. After birth, the newborn develops hyperbilirubinemia that can lead to kernicterus.

About 15% of White, 5%–8% of Black, and fewer than 1% of Asian individuals are Rh(D)-negative. Since anti-D immune globulin was introduced, Rh alloimmunization has fallen dramatically, but it still occurs with missed doses, unrecognized bleeding, and inadequate dosing.

  • Prevention with Rho(D) Immune Globulin (RhIG)
  • Routine Prophylaxis

First prenatal visit: ABO, Rh(D) type, and antibody screen for everyone.

About 28 weeks: Repeat the antibody screen and give 300 mcg RhIG to unsensitized Rh(D)-negative patients (it protects for about 12 weeks).

After delivery: If the newborn is Rh(D)-positive (or unknown), give 300 mcg within 72 hours ; if missed, it can still be given up to 28 days later.

Additional Indications (unsensitized Rh(D)-negative patients)

Ectopic pregnancy and molar pregnancy.

Spontaneous or induced abortion or pregnancy loss at 12 weeks or later (ACOG's 2024 Clinical Practice Update suggests forgoing routine Rh testing and RhIG before 12 weeks ).

Antepartum bleeding, abdominal trauma, and stillbirth.

Amniocentesis, chorionic villus sampling, and external cephalic version .

A 50-mcg dose is sometimes used for first-trimester events when RhIG is given.

Quantifying Fetomaternal Hemorrhage

One 300-mcg vial neutralizes about 30 mL of fetal whole blood (15 mL of fetal red cells) . A screening rosette test after delivery identifies larger hemorrhages, and a Kleihauer-Betke test or flow cytometry quantifies them to calculate the number of vials. Quantification is especially important after abdominal trauma, abruption, or stillbirth.

Weak D

Many people with a serologic "weak D" phenotype have RHD genotypes (weak D types 1, 2, or 3) that let them be managed as Rh(D)-positive, avoiding unnecessary RhIG. Genotyping is recommended when serologic weak D is found.

Managing the Sensitized Pregnancy

Once anti-D (or another clinically significant antibody) is found, RhIG no longer helps. Management aims to detect fetal anemia early.

Antibody titer: Repeat roughly every 4 weeks until about 24 weeks, then every 2 weeks. A critical titer , commonly 1:16 (range 1:8–1:32 by laboratory), is the level associated with a significant risk of fetal hydrops.

Determine fetal antigen status: Test the reproductive partner. If the partner is Rh(D)-negative, the fetus is Rh(D)-negative and unaffected. If the partner is heterozygous or unknown, determine fetal RHD status by cell-free DNA in maternal blood or by amniocentesis.

At or above the critical titer with an antigen-positive fetus: Begin middle cerebral artery peak systolic velocity (MCA-PSV) Doppler every 1–2 weeks from about 16–18 weeks. Anemic fetuses have thinner, faster-flowing blood, so MCA-PSV above 1.5 multiples of the median (MoM) predicts moderate-to-severe anemia.

Elevated MCA-PSV or hydrops: Cordocentesis to measure fetal hematocrit and intrauterine transfusion of O-negative, irradiated, cytomegalovirus-safe red cells at a fetal therapy center.

Delivery: Usually at about 37–38 weeks , earlier if transfusions are required; the newborn may need phototherapy, exchange transfusion, or top-up transfusions.

A history of a previously affected fetus or newborn skips titer-based monitoring and goes directly to MCA Doppler surveillance, because titers do not predict severity in later pregnancies.

Other Red-Cell Antibodies

Antibody Clinical Significance

Anti-Kell (K1) Causes severe anemia by suppressing fetal red-cell production as well as hemolysis; titers correlate poorly, so a lower critical titer ( 1:8 ) and early MCA Doppler are used. Often follows prior transfusion

  • Anti-c, anti-E, anti-Fya (Duffy), anti-Jka (Kidd) Can cause HDFN; managed like anti-D
  • Anti-Lewis, anti-I, anti-P Usually IgM; do not cause HDFN

ABO incompatibility (mother type O, infant A or B) Common but usually mild neonatal jaundice; not prevented by RhIG and does not require antenatal monitoring

Clinical Pitfalls

The 28-week dose does not replace the postpartum dose. If the newborn is Rh(D)-positive, give anti-D immune globulin after delivery even though the patient received it at 28 weeks.

Passive anti-D after RhIG: An antibody screen done within weeks of RhIG often shows a low anti-D titer (usually 1:4 or less) from the injection itself. This passive antibody is not sensitization and does not mean further doses should be withheld; check the timing of the last dose.

Partner testing: If the reproductive partner is confirmed Rh(D)-negative, the fetus is Rh(D)-negative, but routine prophylaxis is still commonly given because paternity cannot always be confirmed.

Consent: Rho(D) immune globulin is a pooled plasma product, so explain it and obtain consent; some patients, including some Jehovah's Witnesses, may decline blood-derived products.

Timing of the antibody screen: Draw the 28-week antibody screen before giving RhIG, so the result reflects true sensitization.

Every pregnancy restarts the process: Rh(D)-negative, unsensitized patients need the same screening and prophylaxis in each new pregnancy.